In recent years, several genetic changes, such as MYCN amplification [3], loss of heterozygosity (LOH) of chromosomes 1p and 11q [4, 5], and 17q gain, have been identified in neuroblastoma specimens, which have been shown to correlate with its aggressive clinical features [6]. This evidence concerns the gene MYCN and neuroblastoma.